A Systematic Review and Meta-Analysis of Cancer Patients Affected by a Novel Coronavirus.

Autor:	Venkatesulu BP; Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, USA.; Department of Radiation Oncology, Loyola University, Maywood, IL., Chandrasekar VT; Department of Gastroenterology and Hepatology, University of Kansas Medical Center, Kansas City, KS, USA., Girdhar P; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India., Advani P; Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Institutes of Health, National Cancer Institute, Bethesda, MD, USA., Sharma A; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Elumalai T; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK., Hsieh CE; Department of Radiation Oncology, Institute for Radiological Research, Chang Gung Memorial Hospital at Linkou and Chang Gung University, Taoyuan City, Taiwan.; Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston and The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Elghazawy HI; Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Abbaseya, Cairo, Egypt., Verma V; Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA, USA., Krishnan S; Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL, USA.
Jazyk:	angličtina
Zdroj:	JNCI cancer spectrum [JNCI Cancer Spectr] 2021 Feb 24; Vol. 5 (2), pp. pkaa102. Date of Electronic Publication: 2021 Feb 24 (Print Publication: 2021).
DOI:	10.1093/jncics/pkaa102
Abstrakt:	Background: Cancer patients with coronavirus disease 2019 (COVID-19) have been reported to have double the case fatality rate of the general population. Methods: A systematic search of PubMed, Embase, and Cochrane Central was done for studies on cancer patients with COVID-19. Pooled proportions were calculated for categorical variables. Odds ratio (OR) and forest plots (random-effects model) were constructed for both primary and secondary outcomes. Results: This systematic review of 38 studies and meta-analysis of 181 323 patients from 26 studies included 23 736 cancer patients. Our meta-analysis shows that cancer patients with COVID-19 have a higher likelihood of death (n = 165 980, OR = 2.54, 95% confidence interval [CI] = 1.47 to 4.42), which was largely driven by mortality among patients in China. Cancer patients were more likely to be intubated. Among cancer subtypes, the mortality was highest in hematological malignancies (n = 878, OR = 2.39, 95% CI = 1.17 to 4.87) followed by lung cancer (n = 646, OR = 1.83, 95% CI = 1.00 to 3.37). There was no association between receipt of a particular type of oncologic therapy and mortality. Our study showed that cancer patients affected by COVID-19 are a decade older than the normal population and have a higher proportion of comorbidities. There was insufficient data to assess the association of COVID-19-directed therapy and survival outcomes in cancer patients. Conclusion: Cancer patients with COVID-19 disease are at increased risk of mortality and morbidity. A more nuanced understanding of the interaction between cancer-directed therapies and COVID-19-directed therapies is needed. This will require uniform prospective recording of data, possibly in multi-institutional registry databases. (© The Author(s) 2021. Published by Oxford University Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu